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Abstract
Background—The burden of cerebral white matter hyperintensities (WMH) is associated with 
an increased risk of stroke, dementia, and death. WMH are highly heritable, but their genetic 
underpinnings are incompletely characterized. To identify novel genetic variants influencing 
WMH burden, we conducted a meta-analysis of multi-ethnic genome-wide association studies.
Methods and Results—We included 21,079 middle-aged to elderly individuals from 29 
population-based cohorts, who were free of dementia and stroke and were of European 
(N=17,936), African (N=1,943), Hispanic (N=795), and Asian (N=405) descent. WMH burden 
was quantified on MRI either by a validated automated segmentation method or a validated visual 
grading scale. Genotype data in each study were imputed to the 1000 Genomes reference. Within 
each ethnic group, we investigated the relationship between each SNP and WMH burden using a 
linear regression model adjusted for age, sex, intracranial volume, and principal components of 
ancestry. A meta-analysis was conducted for each ethnicity separately and for the combined 
sample. In the European descent samples, we confirmed a previously known locus on chr17q25 
(p=2.7×10−19) and identified novel loci on chr10q24 (p=1.6×10−9) and chr2p21 (p=4.4×10−8). In 
the multi-ethnic meta-analysis, we identified two additional loci, on chr1q22 (p=2.0×10−8) and 
chr2p16 (p=1.5×10−8). The novel loci contained genes that have been implicated in Alzheimer’s 
disease (chr2p21, chr10q24), intracerebral hemorrhage (chr1q22), neuroinflammatory diseases 
(chr2p21), and glioma (chr10q24, chr2p16).
Conclusions—We identified four novel genetic loci that implicate inflammatory and glial 
proliferative pathways in the development of white matter hyperintensities in addition to 
previously-proposed ischemic mechanisms.
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Introduction
Cerebral white matter hyperintensities (WMH) are common in the aging population and are 
associated with an increased risk of stroke, vascular cognitive impairment, dementia, and 
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death.1 The prevalence and severity of WMH increase with advancing age and the presence 
of vascular risk factors, notably hypertension.2 The pathophysiology of WMH is poorly 
understood but likely reflects ischemic or degenerative damage to the small vessels of the 
brain, leading to chronic cerebral hypoperfusion and myelin rarefaction.3 Perivascular 
inflammation is a prominent pathological feature in WMH4 and WMH burden has been 
associated with circulating biomarkers of inflammation, including high-sensitivity C-
reactive protein, Interleukin-6, lipoprotein-associated phospholipase A2, and 
myeloperoxidase.5, 6
Twin and family studies suggest that the heritability of WMH is 55–80%.7–9 Yet, few 
genetic variants have been identified and they explain only a small proportion of the 
phenotypic variance,10 suggesting that additional variants remain to be discovered. The first 
meta-analysis of genome-wide association studies (GWAS) on WMH burden identified a 
new locus on Chr17q2511, which has been replicated in several studies.12–14 It comprised 
9361 individuals of European descent and used genome-wide genotype data imputed to the 
HapMap2 reference panel.11 In recent years, the 1000 Genomes reference panel has become 
available for genotype imputation, enabling the study of millions of SNPs including low 
frequency variants. Furthermore, additional studies with brain MRI data have obtained 
genome-wide genotype data, including studies in populations of African, Hispanic, and 
Asian descent. Here, we conducted a meta-GWAS of WMH burden based on 1000 Genomes 
imputation data in 21,079 individuals from 4 ethnic groups. To gain pathophysiological 
insights, we also investigated the joint effect on WMH burden of genetic loci for high blood 
pressure levels, a strong predictor of WMH burden, and for Alzheimer’s disease and stroke, 
which, both, have co-morbid loads of WMH.
Subject and Methods
Study participants were from 29 population-based cohorts. All participating studies worked 
cooperatively to address issues related to phenotype harmonization and covariate selection 
and to develop analytic plans for within-study GWAS analyses and for meta-analyses of 
results. Each study received institutional review board approval of its consent procedures, 
examination and surveillance, DNA collection and use, and data access and distribution. All 
participants in this study gave written informed consent for study participation, MRI 
scanning, and use of DNA. Details of cohort recruitment, risk factor assessment, 
phenotyping, and genotyping are described in the Supplemental Material. Briefly, 
participants were excluded if they lacked information on MRI or genotypes or if they had 
clinical dementia or stroke. If data on clinical stroke were missing in a given cohort, 
presence of MRI infarcts extending into the cortical grey matter was used as an exclusion 
criterion.
MRI scans
In each study, MRI scans were performed and interpreted in a standardized fashion, without 
reference to demographic or clinical information. The field strength of the scanners used 
ranged from 0.5 to 3.0 Tesla. T1-and T2-weighted scans in the axial plane were obtained for 
all participants. These were complemented by either scans obtained with fluid attenuation 
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inversion recovery or proton density sequences to allow better separation of WMH and 
cerebrospinal fluid. A validated automated segmentation method (23 cohorts) or a validated 
visual grading scale (6 cohorts) was used to quantify WMH burden. Details of the applied 
WMH quantification method per cohort can be found in the Supplemental Material.
Comparability between the volumetric and visual scales has been evaluated previously and 
was shown to be similar across cohorts.11 Details about the extensive phenotype 
harmonization procedures performed prior to GWAS have been previously reported.11
Genotyping & imputation
As described in the Supplemental Material, the participating studies used different 
genotyping platforms and performed extensive quality control (QC) analyses. Briefly, 
participant-specific quality controls filters were applied based on missing call rate, cryptic 
relatedness, sex mismatch, principal component analysis, and number of Mendelian errors 
per individual (for studies with family data). SNP-specific quality controls included filters 
for call rate, minor allele frequency Hardy-Weinberg equilibrium, differential missingness 
by outcome or genotype, and imputation quality. After QC analysis, genotype data in each 
study were used to impute to the 1000 Genomes reference panel (version available in 
Supplemental Material). Because not all versions of 1000 Genomes that were used included 
copy number variations, we only analyzed single nucleotide polymorphisms (SNPs), which 
totaled 14,227,402.
Statistical analyses and meta-analysis
Statistical analyses were performed similar to the previous meta-GWAS on WMH burden.8 
Analyses were carried out separately by ethnic group. Briefly, within each study, we 
evaluated the relationship between each SNP and WMH burden using a linear regression 
model, assuming an additive genetic effect.11 WMH burden was expressed as ln(WMH 
burden+1) to reduce the skewness of its distribution. We adjusted for age, sex, intracranial 
volume and, if indicated, principal components of ancestry. No adjustment for intracranial 
volume was performed in studies that used a visual grading scale, since these scales take 
head size into account. ARIC and CHS also adjusted for study site, and FHS adjusted for 
familial structure (Supplemental Material).
We performed a weighted z-score-based fixed-effect meta-analysis implemented in 
METAL15. We chose this methodology for several reasons: First, the measures of WMH 
were not expressed on the same scale in the various studies, thus a random-effect meta-
analysis was not possible. Second, the focus of our meta-analyses was to identify new loci 
for WMH, thus we sought to maximize power of our study. Fixed-effect models have been 
shown to be more powerful than random-effect models even in the presence of between-
study heterogeneity.16 Third, Senn stated that “the choice of fixed effects or random effects 
meta-analysis should not be made on the basis of perceived heterogeneity but on the basis of 
purpose”.17 Our purpose was to identify new associations rather than accurately estimating 
effect size of well-validated variants, which would need to account for possible between-
population heterogeneity. For each SNP, the z-statistic, derived from the P-value and 
direction of effect, was weighted by the effective sample size, which is the product of the 
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sample size and the product of the sample size and the ratio of the empirically observed 
dosage variance to the expected binomial dosage variance for imputed SNPs. A combined 
estimate was obtained by summing the weighted z-statistics and dividing by the summed 
weights. Prior to meta-analysis, SNPs were filtered out within each cohort if they had a poor 
imputation quality (Rsq > 0.3), a MAF < 0.005, and an effective sample size < 50. The 
genomic control parameter was calculated and used to remove any residual population 
stratification within cohort and in the combined meta-analyses. We performed meta-analyses 
for each ethnicity separately and also combined results in a multi-ethnic meta-analysis, 
correcting for genomic inflation.
To gain a better understanding of each genome-wide significant locus (P<5×10−8), we 
performed a step-wise analysis to examine whether additional variants at the identified loci 
were independently associated with WMH burden, after adjusting for the effects of the most 
significant SNP. Each study repeated the primary analyses adjusting for the top-SNP at each 
of the significant loci (European ancestry sample only) and the results were then meta-
analyzed as described above.
To study whether identified SNPs may cause damage of protein function, we used the 
prediction tools PolyPhen-218 and SIFT.19 To examine whether identified SNPs had an 
impact on gene regulation, we used a heuristic scoring system implemented in 
RegulomeDB.20 In secondary analyses, we studied the joint effect of loci for WMH-related 
traits. We extracted SNPs from the meta-analysis that have been reported to be associated 
with blood pressure,21 Alzheimer’s disease,22 and stroke,23–25 and meta-analyzed their 
effects using a weighted z-score method.26 Additional details are provided in the 
Supplemental Material.
Results
Demographic and clinical characteristics of the participating cohorts are shown in the 
Supplemental Material (Table S1). In total, we included 17,936 individuals of European 
descent, 1,943 African-Americans, 795 individuals of Hispanic descent, and 405 individuals 
of Asian descent (204 Chinese and 201 Malays). There was no evidence of test statistic 
inflation in the individual cohort analyses or the ethnic-specific and overall meta-analyses 
(Figure S1).
Table 1 shows the genome-wide significant loci (p < 5×10−8) in the meta-analyses of the 
overall sample and of each ethnic group. Manhattan-plots are displayed in the Supplemental 
Material (Figure S2). In the European descent samples, we identified three regions with 
genome-wide significant SNPs: on chr17q25 (top-SNP: rs7214628, p=2.7×10−19); on 
chr10q24 (top-SNP: rs72848980, p=1.6×10−9); and on chr2p21 (top-SNP: rs11679640; 
p=4.4×10−8) (Table 1). In the samples of African, Hispanic, and Asian descent, no variant 
reached genome-wide significance likely due to limited power. In the multi-ethnic analyses, 
we identified two additional regions, on chr1q22 (top-SNP: rs2984613, p=2.0×10−8) and 
chr2p16 (top-SNP: rs78857879, p=1.5×10−8) (Table 1). Directions of effect for these SNPs 
in each of the cohorts are shown in Table S2 and information on suggestive loci 
(p<1.0×10−5) in Table S3.
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The chr17q25 locus contained 147 genome-wide significant SNPs in the meta-analysis of 
the European descent samples (Figure 1). The top-SNP from chr17q25 (rs7214628) lies 
close (2.9 kb) to TRIM65 and is in high linkage disequilibrium (LD) with rs3744028, 
reported in our previous GWAS (r2=0.99).11 Analyses of association adjusting for the effect 
of rs7214628 were carried out to determine whether secondary signals were present across 
the region. None of the 147 SNPs remained genome-wide significant after accounting for 
the effect of rs7214628 (Figure S3). Ten were nominally significant (p < 0.05) including 4 
intronic variants and one missense variant in ACOX1, 3 intronic variants and one variant 
near FBF1, and one intronic variant in MRPL38, but would not survive a multiple testing 
significance threshold. Functional annotation of the genome-wide significant SNPs in the 
chr17q25 region identified 7 missense variants, 4 eQTLs influencing gene expression of 
TRIM47, 10 SNPs with a likely functional impact on gene regulation (RegulomeDB score ≤ 
3), and 6 synonymous or intronic SNPs with high levels of evolutionary conservation. 
Association of these SNPs with WMH burden in each ethnic group is shown in Table 2. The 
direction of association was generally consistent in Europeans, Hispanics, and African-
Americans but was opposite in Asians. This pattern was also observed across the larger set 
of 147 genome-wide significant SNPs, suggesting possible heterogeneity of effects in Asian 
populations. Among the putatively functional SNPs, those with the strongest LD with 
rs7214628 in Europeans were the TRIM47 eQTL rs3744017 and the putatively-regulatory 
SNP rs3744020, located in an intron of TRIM47. Interestingly, these 2 SNPs had also the 
lowest p value in African-Americans (p=0.08, rs3744017; p=0.09. rs3744020). We observed 
a nominally significant association (p <0.05) for the regulatory SNP rs1551619 in Hispanics. 
This SNP was in moderately high LD with rs7214628 in both Europeans and Hispanics 
(r2=0.74).
The chr10q24 locus contained 12 genome-wide significant SNPs in the meta-analysis of the 
European descent samples and 7 SNPs in the overall meta-analysis. These mapped to a 555 
kb region from base pair position 105080575 to 105635537 (Figure 1). The top-SNP from 
chr10q24 (rs7894407) lies within an intron of PDCD11. Analyses accounting for the effects 
of rs7894407 revealed that the SNPs in SH3PXD2A (rs12357919: p=2.7×10−3, rs4630220, 
p=2.7×10−3, rs7909791: p=3.9×10−7), and NEURL (rs72848980, p=1.9×10−3) were 
independently associated with WMH burden (Figure S3). In the multi-ethnic meta-analysis, 
rs72848980 (NEURL) had the lowest p-value within the chr10q24 locus. These 4 SNPs were 
in low LD with rs7894407 (r2 between 0 and 0.33), and in moderate to low LD with each 
other (Table S4). Functional annotation of the genome-wide significant SNPs identified a 
missense variant in TAF5 (rs10883859, Ser/Ala). The exonic variant in CALHM1 
(rs4918016) was synonymous. Annotation of the genome-wide significant SNPs for 
predicted function on gene regulation identified 2 SNPs (RegulomeDB score ≤ 3): 
rsl2357919 located in an intron of SH3PXD2A; and rs729211 located in the 3’untranslated 
region of CALMH1, and identified as an eQTL influencing gene expression of USMG5. 
rs11191772 was a highly conserved intronic SNP in SH3PXD2A. Association of these SNPs 
with WMH burden in each ethnic group is shown in Table 3. rs729211, rs4918016, and 
rs11191772, identified in the multi-ethnic meta-analyses, show trends toward nominal 
significance in African-Americans and Hispanics.
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The chr2p16 locus contained one genome-wide significant SNP (rs78857879) in the multi-
ethnic meta-analysis. This SNP maps to an intron of EFEMP1 (Figure 1) and was predicted 
to have a putatively functional impact on gene regulation (RegulomeDB score=3a). This 
SNP was nominally significant in the groups of European and African descent (p=2.9×10−7 
and 2.2×10−2, respectively) (Table 1).
The chr1q22 locus contained one genome-wide significant SNP (rs2984613) in the multi-
ethnic meta-analysis. Although the association of rs2984613 with WMH burden was only 
nominally significant in individuals of European, African, and Hispanic descent 
(p=2.4×10−5; 1.4×10−5; and 1.5×10−2, respectively), it reached genome-wide significance in 
the multi-ethnic meta-analysis combining all ethnic groups. This SNP is located in an intron 
of PMF1/PMF1-BGLAP (Figure 1).
The chr2p21 locus contained one genome-wide significant SNP (rs11679640) near HAAO 
(122 kb) and THADA (316 kb) in individuals of European descent only (Table 1 and Figure 
1). The association of rs11679640 with WMH burden was no longer genome-wide 
significant in the overall meta-analysis and showed opposite direction of effect in the other 
ethnic groups (Table 1), suggesting possible heterogeneity by ethnicity. Although a genome-
wide significant SNP for multiple sclerosis (rs6718520)22 is also nearby (184 kb), this SNP 
was not in LD with rs11679640 and was not significantly associated with WMH burden in 
our study.
To gain additional pathophysiological insights, we investigated whether genetic loci 
identified for WMH-related traits are related to WMH burden.
We showed that genetic loci for blood pressure were significantly related to a higher WMH 
burden (p for systolic blood pressure <0.0001, p for diastolic blood pressure=0.007). We did 
not find a significant association between WMH and loci for Alzheimer’s disease (p =0.12) 
or stroke (p=0.46, in opposite direction).
Discussion
We performed a meta-analysis of genome-wide association studies in samples of European, 
African, Hispanic, and Asian descent. We identified four novel loci on chr10q24, chr2p21, 
chr1q22, chr2p16, and confirmed a previously identified locus on chr17q25. Three of the 
four novel loci (chr10q24, chr1q22, 2p16.1) were associated with WMH burden in more 
than one ethnic group. In addition, we showed that genetic loci influencing systolic blood 
pressure and diastolic blood pressure are associated with WMH burden.
Strengths of our study include the large and diverse sample, the population-based setting, 
and the comprehensive set of common genetic variants examined. However, several 
limitations must be acknowledged. First, the use of different WMH quantification methods 
has constrained our analytical methodology to the meta-analysis of P-values, which is less 
powerful and prevented us to determine an estimate of effect size for the associated SNPs. 
Second, we had a limited sample size of African-Americans, Hispanics, and Asians. This 
limited sample size has reduced our ability to identify new variants in these populations and 
to replicate findings from the larger European sample. However, the inclusion of these 
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groups in a multi-ethnic meta-analysis permitted the identification of two additional loci, 
albeit likely due to increased sample size. Finally, we used different versions of the 1000 
Genomes reference panel for genotype imputation and did not study copy number variations.
We confirmed the association of the locus on chr17q25 in individuals of European descent. 
The genome-wide significant SNPs in this locus include all previously reported SNPs.11 
However, the most significantly associated SNP in this analysis (rs7214628) was not 
previously identified. It lies 2.9 kb away from TRIM65 and in strong LD with rs3744028 
from the original report. Analyses accounting for the effects of rs7214628 showed a strong 
attenuation of effects for all genome-wide significant SNPs, suggesting little evidence for 
multiple independent association signals in this region. Several genome-wide significant 
SNPs in the chr17q25 locus are missense variants in the UNC13D, TRIM47, TRIM65, FBF1, 
and ACOX1 genes. In addition, several SNPs were predicted to have a functional impact on 
gene regulation, including two eQTLs of the TRIM47 gene. The direction of associations of 
SNPs at this locus was generally consistent among populations of European, Hispanic, and 
African descent but not Asians. Power to detect genetic effects in ethnic groups other than 
Europeans was limited. However, SNPs potentially affecting regulation of TRIM47 and 
TRIM65 showed the strongest associations in this region in Hispanics and African-
Americans, while SNPs encoding missense mutations in FBF1, ACOX1, and TRIM65 were 
nominally associated in Asians.
The novel locus on chr10q24 contained genome-wide significant SNPs in introns of 
PDCD11, NEURL, and SH3PXD2A, TAF5 and CALHM1, of which PDCD11, NEURL and 
SH3PXD2A were shown to be independent from each other. PDCD11 encodes the 
programmed cell death 11 and is involved in T-cell induced apoptosis.27 It is expressed in 
glial cells,28 which make up a large proportion of the white matter. NEURL encodes the 
neuralized homolog (Drosophila), an E3 ubiquitin ligase, which has been implicated in 
malignant brain tumors.29, 30 NEURL reportedly causes apoptosis and downregulates 
NOTCH target genes in medulloblastoma.29 NEURL maps to a region that is frequently 
deleted in astrocytoma.30 The SNP in NEURL was also nominally associated in Hispanics in 
the same direction (p=0.04). The SNP in PDCD11 only showed significant associations in 
individuals of European descent. SH3PXD2A, which codes for SH3 and PX domain-
containing protein 2A, has also been implicated in gliomas.31 In addition, it has been 
reported to be involved in amyloid-beta neurotoxicity32 and implicated in Alzheimer’s 
disease.33 TAF5 contained a missense variant, although without predicted damage on protein 
function. TAF5 codes for transcription initiation factor TFIID subunit 5, which is involved 
in the initiation of transcription by RNA polymerase II. CALHM1 codes for calcium 
homeostasis modulator 1, which influences calcium homeostasis and increases cerebral 
amyloid-β (Aβ) peptide production. Interestingly, a missense variant of CALHM1 
(rs2986017) has been associated with late-onset Alzheimer’s disease and Creutzfeldt-Jakob 
disease,34,35 but this SNP was only nominally associated with WMH burden (in the same 
direction) in our study (p=2.5×10−2 in Europeans, and p=3.5×10−2 in the total group). The 
genome-wide significant SNP rs729211, located in the 3’untranslated region of CALHM1, 
had a predicted functional impact on USMG5 gene expression. USMG5 encodes a small 
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subunit of the mitochondrial ATP synthase, which is phylogenetically conserved and is 
thought to have a role in cellular energy metabolism.
The novel locus on chr2p21 that reached genome-wide significance in Europeans but not the 
overall group was located near HAAO. HAAO codes for 3-hydroxyanthranilate 3,4-
dioxygenasee, which catalyzes the synthesis of quinolinic acid (QUIN) from 3-
hydroxyanthranilic acid. QUIN is an excitotoxin whose toxicity is mediated by its ability to 
activate glutamate N-methyl-D-aspartate (NMDA) receptors. QUIN has been implicated in 
neuroinflammatory diseases and may participate in the pathogenesis of Parkinson’s disease, 
Alzheimer’s disease and Huntington disease.36–39 Within the brain, QUIN is produced and 
released by infiltrating macrophages and activated microglia, which are prominent during 
neuroinflammation.36
The novel genome-wide significant SNP on chr1q22 is located in an intron of the read-
through PMF1-BGLAP sequence, which encodes a variant isoform of the polyamine-
modulated factor 1 (PMF1). PMF is a member of a kinetochore-associated multi-protein 
complex, involved in chromosomal alignment and segregation during mitosis.40 Moreover, 
it is a cofactor for the regulation of expression of the rate-limiting enzyme in the catabolic 
pathway of polyamine metabolism.41 Polyamines are important regulators of cell growth 
and cell death and epigenetic modification of PMF1 has been implicated in cancer.42 The 
SNP identified in our analysis (rs2984613) was also identified in a GWAS of non-lobar 
intracerebral hemorrhage (ICH).43 In one study involving two of the cohorts included in this 
work, WML burden was associated with an increased risk of ICH.44 Both ICH and WMH 
share common risk factors such as hypertension, and may share common underlying 
pathological mechanisms involving microangiopathy. Our finding supports such a 
hypothesis.
The locus on chr2p16 contained its top-hit in the intron of EFEMP1, which codes for EGF 
containing fibulin-like extracellular matrix protein 1. EFEMP1 is uniquely upregulated in 
malignant gliomas (different grades) and promotes tumor cell motility and invasion.45 It 
encodes a novel soluble activator of Notch signaling that antagonizes DLL3, an autocrine 
inhibitor or Notch, and promotes tumor cell survival and invasion in a Notch-dependent 
manner.46 EFEMP1 was originally cloned from senescent fibroblasts derived from a patient 
with Werner syndrome a disease of premature aging with diffuse structural abnormalities in 
the brain white matter.47, 48
Intriguingly, three of the five regions significantly associated with WMH burden as well as 
one suggestive locus contained variants in genes implicated in malignant brain tumors of the 
white matter that involve glial cells (TRIM47, NEURL, SH3PXD2A, EFEMP1, and 
NBEAL1). While these tumors can appear as WMH on MRI,49 given the population-based 
setting of the participating studies, the exclusion criteria used in WMH quantification, as 
well as the very low incidence of gliomas (< 5 per 100,000 persons per year)50, the presence 
of unrecognized glioma cases is very unlikely to explain these associations. However, our 
findings suggest that WMH in aging and glioma may share common pathophysiological 
mechanisms, perhaps involving glial cell activation, apoptosis, or both. The role of 
microglia in white matter injury has been demonstrated in several animal models. For 
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example, activated microglia have a critical role in the formation of the excitotoxic white 
matter lesion in a mouse model of periventricular leukomalacia.51 In the rat two-vessel 
occlusion (2VO) model, microglial activation was shown to be an early marker of 
subsequent white matter injury52 and may contribute to induce apoptosis of 
oligodendrocytes in the white matter of these animals.53
In addition to the identification of novel WMH loci, we showed that loci for blood pressure 
were also associated with WMH burden. This further establishes the role of blood pressure 
in WMH. We were not able to identify effects of loci for Alzheimer’s disease and stroke on 
WMH. Pathological processes other than those affecting WMH may be stronger 
determinants of Alzheimer’s disease and therefore variants identified to date may capture 
mostly other mechanisms leading to Alzheimer’s disease. Similarly, stroke is heterogeneous 
and the stroke risk variants tested here are not those reflecting small vessel disease stroke 
subtypes. Shared mechanisms between WMH and stroke are expected mostly for these 
subtypes.
In summary, in a meta-analysis of genome-wide association studies in individuals of 
European, African, Hispanic, and Asian descent, we identified four novel loci and confirmed 
a previous locus. Furthermore, we also report significant associations of blood pressure loci 
with WMH burden. While additional fine mapping at each of the identified loci will be 
needed to uncover the causal genes and variants, a unifying hypothesis emerging from this 
work suggests a central role of neuroinflammation, possibly involving pathological 
mechanisms related to microglial activation and common to gliomas. Future work will be 
needed to establish the importance of these findings in understanding the etiology and 
pathophysiology of WMH and bring us closer to reducing WMH burden and its associated 
clinical manifestations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Authors 
Benjamin F.J. Verhaaren, MD, PhD1,2,*, Stéphanie Debette, MD, PhD3,4,5,6,*, 
Joshua C. Bis, PhD7,*, Jennifer A. Smith, PhD, MPH, MA8,*, M. Kamran Ikram, MD, 
PhD9,10,11, Hieab H. Adams, MSc1,2, Ashley H. Beecham, MSc12, Kumar B. Rajan, 
PhD13, Lorna M. Lopez, PhD14, Sandra Barral, PhD15, Mark A. van Buchem, MD, 
PhD16, Jeroen van der Grond, PhD16, Albert V. Smith, PhD17, Katrin Hegenscheid, 
MD18, Neelum T. Aggarwal, MD13, Mariza de Andrade, PhD19, Elizabeth J. 
Atkinson, PhD19, Marian Beekman, PhD20, Alexa S. Beiser, PhD6,21,22, Susan H. 
Blanton, PhD12,23,24, Eric Boerwinkle, PhD25, Adam M. Brickman, PhD26, R. Nick 
Bryan, MD, PhD27, Ganesh Chauhan, PhD3,5, Christopher P.L.H. Chen, FRCP11, 
Vincent Chouraki, MD, PhD6,21, Anton J.M. de Craen, PhD28, Fabrice Crivello, 
PhD29, Ian J. Deary, PhD14, Joris Deelen, MSc20, Philip L. De Jager, MD, PhD30,31, 
Carole Dufouil, PhD3, Mitchell S.V. Elkind, MD, MSc32, Denis A. Evans, MD13, Paul 
Freudenberger, MSc33, Rebecca F. Gottesman, MD, PhD34, Vilmundur Guðnason, 
Verhaaren et al. Page 9













MD, PhD17,35, Mohamad Habes, PhD27,36, Susan R. Heckbert, MD, PhD7,37, 
Gerardo Heiss, MD38, Saima Hilal, MBBS11, Edith Hofer, PhD39,40, Albert Hofman, 
MD, PhD1, Carla A. Ibrahim-Verbaas, MD1,41, David S. Knopman, MD42, Cora E. 
Lewis, MD, MSPH43, Jiemin Liao, MSc9,10, David C.M. Liewald, BSc14, Michelle 
Luciano, PhD14, Aad van der Lugt, MD, PhD2, Oliver O. Martinez, PhD44, Richard 
Mayeux, MD, MSc26, Bernard Mazoyer, MD, PhD29, Mike Nalls, PhD45, Matthias 
Nauck, MD46, Wiro J. Niessen, PhD2,47,48, Ben A. Oostra, PhD1, Bruce M. Psaty, 
MD, PhD7,37,49,50, Kenneth M. Rice, PhD51, Jerome I. Rotter, MD53,54, Bettina von 
Sarnowski, MD54, Helena Schmidt, MD, PhD34, Pamela J. Schreiner, PhD55, 
Maaike Schuur, MD, PhD1,41, Stephen S. Sidney, MD, MPH56, Sigurdur 
Sigurdsson, MSc17, P. Eline Slagboom, PhD20, David J.M. Stott, MD57, John C. van 
Swieten, MD, PhD41, Alexander Teumer, PhD58, Anna Maria Töglhofer, MSc33, 
Matthew Traylor, MSc59, Stella Trompet, PhD60,61, Stephen T. Turner, MD62, 
Christophe Tzourio, MD, PhD3, Hae-Won Uh, PhD63, André G. Uitterlinden, 
PhD1,64,65, Meike W. Vernooij, MD, PhD1,2, Jing J. Wang, PhD21,22, Tien Y. Wong, 
MD, PhD9,10, Joanna M. Wardlaw, MD14,66, B. Gwen Windham, MD67, Katharina 
Wittfeld, MS68, Christiane Wolf, PhD3, Clinton B. Wright, MD24,69,70,71, Qiong Yang, 
PhD21,22, Wei Zhao, MD, PhD8, Alex Zijdenbos, PhD72, J. Wouter Jukema, MD, 
PhD60,61, Ralph L. Sacco, MD69,70,71, Sharon L.R. Kardia, PhD8, Philippe Amouyel, 
MD, PhD73,74,75,76, Thomas H. Mosley, PhD77, W. T. Longstreth Jr, MD, MPH37,78, 
Charles C. DeCarli, MD44, Cornelia M. van Duijn, PhD1, Reinhold Schmidt, MD39, 
Lenore J. Launer, PhD79,*, Hans J. Grabe, MD80,*, Sudha S. Seshadri, MD6,21,*, M. 
Arfan Ikram, MD, PhD1,2,41,*, and Myriam Fornage, PhD25,81,*
Affiliations
1Dept of Epidemiology, Erasmus MC Univ Medical Ctr, Rotterdam, the Netherlands 
2Dept of Radiology, Erasmus MC Univ Medical Ctr, Rotterdam, the Netherlands 
3Inserm U897, Université Bordeaux Segalen, Bordeaux 4Dept of Neurology, 
Lariboisière Hospital, Paris 5Inserm U1191, Montpellier, France 6Dept of Neurology, 
Boston Univ School of Medicine, Boston, MA 7Cardiovascular Health Research 
Unit, Dept of Medicine, Seattle, WA 8Dept of Epidemiology, School of Public Health, 
Univ of Michigan, Ann Arbor, MI 9Singapore Eye Research Institute, Singapore 
National Eye Centre, National Univ of Singapore & National Univ Health System, 
Singapore 10Dept of Ophthalmology, National Univ of Singapore & National Univ 
Health System, Singapore 11Memory Aging & Cognition Centre, National Univ of 
Singapore, Singapore 12John P. Hussman Institute for Human Genomics, Univ of 
Miami, Miller School of Medicine, Miami, FL 13Rush Univ Medical Ctr, Chicago, IL 
14Centre for Cognitive Ageing & Cognitive Epidemiology, Psychology, Univ of 
Edinburgh, United Kingdom 15Dept of Neurology, Columbia Univ Medical Ctr, New 
York, NY 16Dept of Radiology, Leiden Univ Medical Ctr, Leiden, the Netherlands 
17The Icelandic Heart Association, Kopavogur, Iceland 18Dept of Diagnostic 
Radiology & Neuroradiology, Univ Medicine Greifswald, Greifswald, Germany 
19Division of Biomedical Statistics & Informatics, Mayo Clinic, Rochester, MN 20Dept 
of Molecular Epidemiology, Leiden Univ Medical Ctr, Leiden, the Netherlands 
21National Heart, Lung, & Blood Institute's Framingham Heart Study, Framingham 
Verhaaren et al. Page 10













22Dept of Biostatistics, Boston Univ School of Public Health, Boston, MA 23Dr. John 
T. Macdonald Foundation Dept of Human Genetics, Univ of Miami, Miller School of 
Medicine, Miami, FL 24Neuroscience Program, Univ of Miami, Miller School of 
Medicine, Miami, FL 25Human Genetics Ctr, Univ of Texas Health Science Ctr at 
Houston, Houston, TX 26G.H. Sergievsky Ctr, Taub Institute for Research on 
Alzheimer’s Disease & Aging Brain, Columbia Univ Medical Ctr, New York, NY 
27Dept of Radiology, Perelman School of Medicine, Univ of Pennsylvania Health 
System, Philadelphia, PA 28Dept of Gerontology & Geriatrics, Leiden Univ Medical 
Ctr, Leiden, the Netherlands 29CNRS-CEA UMR5296, Université Bordeaux 
Segalen, Bordeaux 30Harvard Univ, Cambridge 31Brigham and Women's Hospital, 
Boston, MA 32Dept of Neurology, College of Physicians & Surgeons, Dept of 
Epidemiology, Mailman School of Public Health, Columbia Univ, New York, NY 
33Institute of Molecular Biology & Biochemistry, Medical Univ Graz, Graz, Austria 
34Dept of Neurology, Johns Hopkins Univ School of Medicine, Baltimore, MD 
35Faculty of Medicine, Univ of Iceland, Reykjavik, Iceland 36Institutes for Community 
Medicine, Univ Medicine Greifswald, Greifswald, Germany 37Cardiovascular Health 
Research Unit, Dept of Medicine Epidemiology, Univ of Washington, Seattle, WA 
38Dept of Epidemiology, Univ of North Carolina at Chapel Hill School of Public 
Health, Chapel Hill, NC 39Dept of Neurology, Clinical Division of Neurogeriatrics, 
Medical Univ Graz, Graz, Austria 40Institute for Medical Informatics, Statistics & 
Documentation, Medical Univ Graz, Graz, Austria 41Dept of Neurology, Erasmus 
MC Univ Medical Ctr, Rotterdam, the Netherlands 42Dept of Neurology, Mayo Clinic, 
Rochester, MN 43Division of Preventive Medicine, Univ of Alabama, Birmingham, AL 
44Alzheimer's Disease Ctr, Imaging of Dementia & Aging (IdeA) Laboratory, Dept of 
Neurology, Ctr for Neuroscience, Univ of California, Davis, CA 45Laboratory of 
Neurogenetics, The National Institutes of Health, Bethesda, MD 46Clinical Chemistry 
& Laboratory Medicine, Univ Medicine Greifswald, Greifswald, Germany 47Dept of 
Medical Informatics, Erasmus MC Univ Medical Ctr, Rotterdam, the Netherlands 
48Faculty of Applied Sciences, Delft Univ of Technology, Delft, the Netherlands 
49Cardiovascular Health Research Unit, Dept of Medicine Health Services, Univ of 
Washington, Seattle, WA 50Group Health Research Institute, Group Health 
Cooperative, Seattle, WA 51Cardiovascular Health Research Unit, Dept of 
Biostatistics, Univ of Washington, Seattle, WA 52Division of Genomic Outcomes, 
Dept of Pediatrics, Los Angeles Biomedical Research Institute, Harbor-UCLA 
Medical Ctr, Torrance, CA 53Institute for Translational Genomics & Population 
Sciences, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Ctr, 
Torrance, CA 54Dept of Neurology, Univ Medicine of Greifswald, Greifswald, 
Germany 55Division of Epidemiology & Community Health, Univ of Minnesota, 
Minneapolis, MN 56Kaiser Permanente Division of Research, Oakland, CA 
57Institute of Cardiovascular and Medical Sciences, Faculty of Medicine, Univ of 
Glasgow, Glasgow 58Interfaculty Institute for Genetics & Functional Genomics, Univ 
Medicine Greifswald, Greifswald, Germany 59Research Centre for Stroke & 
Dementia, St. George's, Univ of London, London, United Kingdom 60Dept of 
Cardiology, Leiden Univ Medical Ctr, Leiden, the Netherlands 61Interuniversity 
Verhaaren et al. Page 11













Cardiology Institute of the Netherlands, Utrecht, the Netherlands 62Division of 
Nephrology & Hypertension, Mayo Clinic, Rochester, MN 63Dept of Medical 
Statistics & Bioinformatics, Leiden Univ Medical Ctr, Leiden, the Netherlands 64Dept 
of Internal Medicine, Erasmus MC Univ Medical Ctr, Rotterdam, the Netherlands 
65Dept of Clinical Chemistry, Erasmus MC Univ Medical Ctr, Rotterdam, the 
Netherlands 66Brain Research Imaging Centre, SINAPSE Collaboration, Centre for 
Clinical Brain Sciences, Univ of Edinburgh, United Kingdom 67Division of Geriatrics/ 
Gerontology, Univ of Mississippi Medical Ctr, Jackson, MS 68German Ctr for 
Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Germany 69Dept of 
Epidemiology & Public Health Sciences, Univ of Miami, Miller School of Medicine, 
Miami, FL 70Dept of Neurology, Univ of Miami, Miller School of Medicine, Miami, FL 
71Evelyn F. McKnight Brain Institute, Univ of Miami, Miller School of Medicine, 
Miami, FL 72Biospective Inc, Montreal, Quebec, Canada 73Inserm, U744, Lille, 
France 74Université Lille 2, Lille, France 75Institut Pasteur de Lille, Lille, France 76Ctr 
Hospitalier Régional Universitaire de Lille, Lille, France 77Dept of Medicine, Univ of 
Mississippi Medical Ctr, Jackson, MS 78Cardiovascular Health Research Unit, Dept 
of Neurology, Univ of Washington, Seattle, WA 79Laboratory of Epidemiology, 
Demography, & Biometry, National Institute of Aging, The National Institutes of 
Health, Bethesda, MD 80Dept of Psychiatry & Psychotherapy, Univ Medicine 
Greifswald, Greifswald, Germany 81Institute of Molecular Medicine, Univ of Texas 
Health Science Ctr at Houston, Houston, TX
Acknowledgments
The authors thank the staff and participants of each of the studies for their important contributions. The ASPS 
authors thank Birgit Reinhart for her long-term administrative commitment and Ing Johann Semmler for the 
technical assistance at creating the DNA-bank. The ERF study is grateful to P. Veraart for her help in genealogy, J. 
Vergeer for the supervision of the laboratory work and P. Snijders for his help in data collection. The GENOA 
authors acknowledge the contributions of the Mayo Clinic and the University of Texas Health Sciences Center (Eric 
Boerwinkle, Megan L. Grove) for genotyping of the GENOA participants. The LBC1936 study authors thank the 
nurses and staff at the Wellcome Trust Clinical Research Facility (http://www.wtcrf.ed.ac.uk), where subjects were 
tested and the genotyping was performed. The SHIP authors are grateful to Mario Stanke for the opportunity to use 
his server cluster for SNP imputation as well as to Holger Prokisch and Thomas Meitinger (HelmholtzZentrum 
München) for genotyping of the SHIP-TREND cohort. The authors of the Rotterdam Study thank Pascal Arp, Mila 
Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters for their help in creating the GWAS database, and 
Karol Estrada and Maksim V. Struchalin for their support in creation and analysis of imputed data. The 3C-Dijon 
study authors thank A. Boland (Centre National de Génotypage) for her technical help in preparing the DNA 
samples for analyses.
Funding Sources: Age, Gene/Environment Susceptibility-Reykjavik Study (AGES-Reykjavik) This study has 
been funded by NIH contract N01-AG-1-2100, the NIA Intramural Research Program, Hjartavernd (the Icelandic 
Heart Association), and the Althingi (the Icelandic Parliament). The study is approved by the Icelandic National 
Bioethics Committee, VSN: 00–063. Atherosclerosis Risk In Communities Study (ARIC) The Atherosclerosis 
Risk in Communities study was performed as a collaborative study supported by National Heart, Lung, and Blood 
Institute (NHLBI) contracts (HHSN268201100005C, HSN268201100006C, HSN268201100007C, 
HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and 
HHSN268201100012C), R01HL70825, R01HL087641, R01HL59367, and R01HL086694; National Human 
Genome Research Institute contract U01HG004402; and National Institutes of Health (NIH) contract 
HHSN268200625226C. Infrastructure was partly supported by grant NO. UL1RR025005, a component of the NIH 
and NIH Roadmap for Medical Research. This project was also supported by NIH R01 grants HL084099 and 
NS087541 to MF. Austrian Stroke Prevention Study (ASPS) The research reported in this article was funded by 
the Austrian Science Fond (FWF) grant number P20545-P05 and P13180. The Medical University of Graz supports 
the databank of the ASPS. Cardiovascular Health Study (CHS) This CHS research was supported by National 
Heart, Lung, and Blood Institute contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, 
Verhaaren et al. Page 12













N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, HHSN268200960009C, 
N01HC15103; and NHLBI grants HL080295, HL087652, HL105756, HL103612, and HL120393 with additional 
contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was 
provided through AG023629 and AG15928 from the National Institute on Aging (NIA). A full list of principal CHS 
investigators and institutions can be found at CHS-NHLBI.org/. The provision of genotyping data was supported in 
part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and the National 
Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the 
Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors 
and does not necessarily represent the official views of the National Institutes of Health. Chicago Health and 
Aging Project (CHAP) This study was been funded by NIH grant R01-AG-09966 and R01-AG-11101 for the 
parent CHAP study. The genetic analysis was supported by NIH grant R01-AG-030146. This study was approved 
by Rush University Medical Center Internal Review Board. Coronary Artery Risk Development in Young Adults 
Study (CARDIA) The Coronary Artery Risk Development in Young Adults Study (CARDIA) is conducted and 
supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of 
Alabama at Birmingham (HHSN268201300025C & HHSN268201300026C), Northwestern University 
(HHSN268201300027C), University of Minnesota (HHSN268201300028C), Kaiser Foundation Research Institute 
(HHSN268201300029C), and Johns Hopkins University School of Medicine (HHSN268200900041C). CARDIA is 
also partially supported by the Intramural Research Program of the National Institute on Aging (NIA) and an intra-
agency agreement between NIA and NHLBI (AG0005). This manuscript has been reviewed by CARDIA for 
scientific content. Genotyping of the CARDIA participants and statistical data analysis was partially supported by 
National Institutes of Health R01 grants HL084099 and NS087541 to MF. Epidemiology of Dementia in 
Singapore (EDIS) The Singapore Malay Eye Study (SiMES) and the Singapore Chinese Eye. Study (SCES) are 
funded by National Medical Research Council (grants 0796/2003, IRG07nov013, IRG09nov014, STaR/0003/2008 
and CG/SERI/2010) and Biomedical Research Council (grants 09/1/35/19/616), Singapore. The Genome Institute 
of Singapore, Agency for Science, Technology and Research, Singapore provided services for genotyping. The 
Epidemiology of Dementia in Singapore study is supported by the National Medical Research Council, Singapore 
(NMRC/CG/NUHS/2010 [Grant no: R-184-006-184-511]). Dr Ikram received additional funding from the 
Singapore Ministry of Health's National Medical Research Council (NMRC/CSA/038/2013). Erasmus Rucphen 
Family study (ERF) The ERF study as a part of the European Special Populations Research Network 
(EUROSPAN) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947) 
and also received funding from the European Community's Seventh Framework Programme (FP7/2007-2013)/grant 
agreement HEALTH-F4-2007-201413 by the European Commission under the programme "Quality of Life and 
Management of the Living Resources" of 5th Framework Programme (no. QLG2-CT-2002-01254). The ERF study 
was further supported by ENGAGE consortium and CMSB. High-throughput analysis of the ERF data was 
supported by joint grant from Netherlands Organisation for Scientific Research and the Russian Foundation for 
Basic Research (NWO-RFBR 047.017.043). Framingham Heart Study (FHS) This work was supported by the 
National Heart, Lung and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195) and its contract 
with Affymetrix, Inc for genotyping services (Contract No. N02-HL-6-4278). A portion of this research utilized the 
Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department 
of Medicine at Boston University School of Medicine and Boston Medical Center. This study was also supported 
by grants from the National Institute of Neurological Disorders and Stroke (R01 NS17950), the National Heart, 
Lung and Blood Institute (R01 HL093029) and the National Institute of Aging (P30 AG10129, R01s AG033193, 
AG08122, AG16495). Genetic Epidemiology Network of Arteriopathy (GENOA) Support for the Genetic 
Epidemiology Network of Arteriopathy (GENOA) was provided by the National Heart, Lung and Blood Institute 
(HL054464, HL054457, HL054481, HL071917, and HL87660) and the National Institute of Neurological 
Disorders and Stroke (NS041558) of the National Institutes of Health. Leiden Longevity Study (LLS) The Leiden 
Longevity Study has received funding from the European Union's Seventh Framework Programme 
(FP7/2007-2011) under grant agreement n° 259679. This study was supported by a grant from the Innovation-
Oriented Research Program on Genomics (SenterNovem IGE05007), the Centre for Medical Systems Biology, and 
the Netherlands Consortium for Healthy Ageing (grant 050-060-810), all in the framework of the Netherlands 
Genomics Initiative, Netherlands Organization for Scientific Research (NWO), UnileverColworth and by BBMRI-
NL, a Research Infrastructure financed by the Dutch government (NWO 184.021.007). Lothian Birth Cohort 1936 
(LBC1936) This project is funded by the Age UK’s Disconnected Mind programme (http://
www.disconnectedmind.ed.ac.uk) and also by Research Into Ageing (Refs. 251 and 285). The whole genome 
association part of the study was funded by the Biotechnology and Biological Sciences Research Council (BBSRC; 
Ref. BB/F019394/1). Analysis of the brain images was funded by the Medical Research Council Grants G1001401 
and 8200. The imaging was performed at the Brain Research Imaging Centre, The University of Edinburgh (http://
www.bric.ed.ac.uk), a centre in the SINAPSE Collaboration (http://www.sinapse.ac.uk). The work was undertaken 
by The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology (http://
www.ccace.ed.ac.uk), part of the cross council Lifelong Health and Wellbeing Initiative (Ref. G0700704/84698). 
Funding from the BBSRC, Engineering and Physical Sciences Research Council (EPSRC), Economic and Social 
Research Council (ESRC), Medical Research Council (MRC) and Scottish Funding Council through the SINAPSE 
Collaboration is gratefully acknowledged. Northern Manhattan Study (NOMAS) The Northern Manhattan Study 
(NOMAS) is supported by the NINDS (grants R37 NS29993 and K02 NS 059729). Genome-wide data were 
supported by the Evelyn F. McKnight Brain Institute. PROspective Study of Pravastatin in the Elderly at Risk 
(PROSPER) The PROSPER study was supported by an investigator initiated grant obtained from Bristol-Myers 
Verhaaren et al. Page 13













Squibb. Prof. Dr. J. W. Jukema is an Established Clinical Investigator of the Netherlands Heart Foundation (grant 
2001 D 032). Support for genotyping was provided by the seventh framework program of the European 
commission (grant 223004) and by the Netherlands Genomics Initiative (Netherlands Consortium for Healthy 
Aging grant 050-060-810). Rotterdam Study (RS I, RSII, RS III) The generation and management of GWAS 
genotype data for the Rotterdam Study is supported by the Netherlands Organisation of Scientific Research NWO 
Investments (nr. 175.010.2005.011, 911-03-012). This study is funded by the Research Institute for Diseases in the 
Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific 
Research (NWO) project nr. 050-060-810. Further funding was received from the Netherlands Heart Foundation 
(2009B102) and a Veni-grant (916.13.054). The Rotterdam Study is funded by Erasmus Medical Center and 
Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the 
Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry 
for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. Study of 
Health in Pomerania (SHIP and SHIP-TREND) SHIP: The Study of Health in Pomerania (SHIP) is supported by 
the German Federal Ministry of Education and Research (grants 01ZZ9603, 01ZZ0103 and 01ZZ0403). Genome-
wide data and MRI scans were supported by the Federal Ministry of Education and Research (grant 03ZIK012) and 
a joint grant from Siemens Healthcare, Erlangen, Germany, and the Federal State of Mecklenburg–West Pomerania. 
The University of Greifswald is a member of the Center of Knowledge Interchange program of the Siemens AG 
and the Caché Campus program of the InterSystems GmbH. SHIP-TREND-0: This cohort is part of the Community 
Medicine Research net (CMR) of the University of Greifswald, which is funded by the German Federal Ministry of 
Education and Research and the German Ministry of Cultural Affairs, as well as by the Social Ministry of the 
Federal State of Mecklenburg–West Pomerania. CMR encompasses several research projects that share data from 
the population-based Study of Health in Pomerania (SHIP; see URLs). MRI scans were supported by a joint grant 
from Siemens Healthcare, Erlangen, Germany, and the Federal State of Mecklenburg–West Pomerania. The SHIP-
TREND cohort was supported by the Federal Ministry of Education and Research (grant 03ZIK012). Three-City 
Dijon Study (3C-Dijon Study) The 3C Study is conducted under a partnership agreement between the Institut 
National de la Santé et de la Recherche Médicale (INSERM), the Victor Segal en-Bordeaux II University, and 
Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 
3C Study is also supported by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la 
Santé, Mutuelle Générale de l'Education Nationale (MGEN), Institut de la Longévité, Conseils Régionaux of 
Aquitaine and Bourgogne, Fondation de France, and Ministry of Research-INSERM Programme “Cohortes et 
collections de données biologiques.” Lille Génopôle received an unconditional grant from Eisai. This work was 
supported by the National Foundation for Alzheimer’s Disease and Related Disorders, the Institut Pasteur de Lille 
and the Centre National de Génotypage. Washington Heights-Inwood Columbia Aging Project (WHICAP) We 
would like to acknowledge the following grants for supporting this study: P01-AG007232, R01-AG037212, and 
NIHR01-AG034189.
References
1. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic 
resonance imaging: systematic review and meta-analysis. BMJ. 2010; 341:c3666. [PubMed: 
20660506] 
2. Launer LJ. Epidemiology of white matter lesions. Top Magn Reson Imaging. 2004; 15:365–367. 
[PubMed: 16041288] 
3. Pantoni L. Pathophysiology of age-related cerebral white matter changes. Cerebrovasc Dis. 2002; 
13(Suppl 2):7–10. [PubMed: 11901236] 
4. Gouw AA, Seewann A, van der Flier WM, Barkhof F, Rozemuller AM, Scheltens P, et al. 
Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. 
J Neurol Neurosurg Psychiatry. 2011; 82:126–135. [PubMed: 20935330] 
5. Fornage M, Chiang YA, O'Meara ES, Psaty BM, Reiner AP, Siscovick DS, et al. Biomarkers of 
Inflammation and MRI-Defined Small Vessel Disease of the Brain: The Cardiovascular Health 
Study. Stroke. 2008; 39:1952–1959. [PubMed: 18436879] 
6. Wright CB, Moon Y, Paik MC, Brown TR, Rabbani L, Yoshita M, et al. Inflammatory biomarkers 
of vascular risk as correlates of leukoariosis. Stroke. 2009; 40:3466–3471. [PubMed: 19696417] 
7. Carmelli D, DeCarli C, Swan GE, Jack LM, Reed T, Wolf PA, et al. Evidence for genetic variance 
in white matter hyperintensity volume in normal elderly male twins. Stroke. 1998; 29:1177–1181. 
[PubMed: 9626291] 
8. Atwood LD, Wolf PA, Heard-Costa NL, Massaro JM, Beiser A, D'Agostino RB, et al. Genetic 
variation in white matter hyperintensity volume in the Framingham Study. Stroke. 2004; 35:1609–
1613. [PubMed: 15143299] 
Verhaaren et al. Page 14













9. Turner ST, Jack CR, Fornage M, Mosley TH, Boerwinkle E, de Andrade M. Heritability of 
leukoaraiosis in hypertensive sibships. Hypertension. 2004; 43:483–487. [PubMed: 14718359] 
10. Freudenberger P, Schmidt R, Schmidt H. Genetics of age-related white matter lesions from linkage 
to genome wide association studies. J Neurol Sci. 2012; 322:82–86. [PubMed: 22795385] 
11. Fornage M, Debette S, Bis JC, Schmidt H, Ikram MA, Dufouil C, et al. Genome-wide association 
studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol. 2011; 
69:928–939. [PubMed: 21681796] 
12. Verhaaren BF, de Boer R, Vernooij MW, Rivadeneira F, Uitterlinden AG, Hofman A, et al. 
Replication study of chr17q25 with cerebral white matter lesion volume. Stroke. 2011; 42:3297–
3299. [PubMed: 21868733] 
13. Adib-Samii P, Rost N, Traylor M, Devan W, Biffi A, Lanfranconi S, et al. 17q25 Locus is 
associated with white matter hyperintensity volume in ischemic stroke, but not with lacunar stroke 
status. Stroke. 2013; 44:1609–1615. [PubMed: 23674528] 
14. Tabara Y, Igase M, Okada Y, Nagai T, Uetani E, Kido T, et al. Association of Chr17q25 with 
cerebral white matter hyperintensities and cognitive impairment: the J-SHIPP study. Eur J Neurol. 
2013; 20:860–862. [PubMed: 23020117] 
15. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide 
association scans. Bioinformatics. 2010; 26:2190–2191. [PubMed: 20616382] 
16. Pereira TV, Patsopoulos NA, Salanti G, Ioannidis JP. Discovery properties of genome-wide 
association signals from cumulatively combined data sets. Am J Epidemiol. 2009; 170:1197–1206. 
[PubMed: 19808636] 
17. Senn S. Trying to be precise about vagueness. Stat Med. 2007; 26:1417–1430. [PubMed: 
16906552] 
18. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and 
server for predicting damaging missense mutations. Nat Methods. 2010; 7:248–249. [PubMed: 
20354512] 
19. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein 
function using the SIFT algorithm. Nat Protoc. 2009; 4:1073–1081. [PubMed: 19561590] 
20. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al. Annotation of 
functional variation in personal genomes using RegulomeDB. Genome Res. 2012; 22:1790–1797. 
[PubMed: 22955989] 
21. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, et al. Genetic variants in 
novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011; 478:103–
109. [PubMed: 21909115] 
22. Bertram LMM, Mullin K, Blacker D, Tanzi R. The AlzGene Database. Alzheimer Research 
Forum. Available at: http://www.alzgene.org. 
23. Ikram MA, Seshadri S, Bis JC, Fornage M, DeStefano AL, Aulchenko YS, et al. Genomewide 
association studies of stroke. N Engl J Med. 2009; 360:1718–1728. [PubMed: 19369658] 
24. Traylor M, Farrall M, Holliday EG, Sudlow C, Hopewell JC, Cheng YC, et al. Genetic risk factors 
for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of 
genome-wide association studies. Lancet Neurol. 2012; 11:951–962. [PubMed: 23041239] 
25. Holliday EG, Maguire JM, Evans TJ, Koblar SA, Jannes J, Sturm JW, et al. Common variants at 
6p21.1 are associated with large artery atherosclerotic stroke. Nat Genet. 2012; 44:1147–1151. 
[PubMed: 22941190] 
26. Dastani Z, Hivert MF, Timpson N, Perry JR, Yuan X, Scott RA, et al. Novel loci for adiponectin 
levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 
45,891 individuals. PLoS Genet. 2012; 8:e1002607. [PubMed: 22479202] 
27. Lacana E, D'Adamio L. Regulation of Fas ligand expression and cell death by apoptosis-linked 
gene 4. Nat Med. 1999; 5:542–547. [PubMed: 10229231] 
28. Sweet T, Khalili K, Sawaya BE, Amini S. Identification of a novel protein from glial cells based 
on its ability to interact with NF-kappaB subunits. J Cell Biochem. 2003; 90:884–891. [PubMed: 
14624448] 
Verhaaren et al. Page 15













29. Teider N, Scott DK, Neiss A, Weeraratne SD, Amani VM, Wang Y, et al. Neuralized1 causes 
apoptosis and downregulates Notch target genes in medulloblastoma. Neuro Oncol. 2010; 
12:1244–1256. [PubMed: 20847082] 
30. Nakamura H, Yoshida M, Tsuiki H, Ito K, Ueno M, Nakao M, et al. Identification of a human 
homolog of the Drosophila neuralized gene within the 10q25.1 malignant astrocytoma deletion 
region. Oncogene. 1998; 16:1009–1019. [PubMed: 9519875] 
31. Stylli SS, I ST, Kaye AH, Lock P. Prognostic significance of Tks5 expression in gliomas. J Clin 
Neurosci. 2012; 19:436–442. [PubMed: 22249020] 
32. Malinin NL, Wright S, Seubert P, Schenk D, Griswold-Prenner I. Amyloid-beta neurotoxicity is 
mediated by FISH adapter protein and ADAM12 metalloprotease activity. Proc Natl Acad Sci U S 
A. 2005; 102:3058–3063. [PubMed: 15710903] 
33. Harold D, Jehu L, Turic D, Hollingworth P, Moore P, Summerhayes P, et al. Interaction between 
the ADAM12 and SH3MD1 genes may confer susceptibility to late-onset Alzheimer's disease. Am 
J Med Genet B Neuropsychiatr Genet. 2007; 144B:448–452. [PubMed: 17440933] 
34. Boada M, Antunez C, Lopez-Arrieta J, Galan JJ, Moron FJ, Hernandez I, et al. CALHM1 P86L 
polymorphism is associated with late-onset Alzheimer's disease in a recessive model. J Alzheimers 
Dis. 2010; 20:247–251. [PubMed: 20164592] 
35. Calero O, Bullido MJ, Clarimon J, Hortiguela R, Frank-Garcia A, Martinez-Martin P, et al. 
Genetic variability of the gene cluster CALHM 1–3 in sporadic Creutzfeldt-Jakob disease. Prion. 
2012; 6:407–412. [PubMed: 22874670] 
36. Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. FEBS J. 2012; 279:1356–1365. 
[PubMed: 22248144] 
37. Schwarcz R, Okuno E, White RJ, Bird ED, Whetsell WO Jr. 3-Hydroxyanthranilate oxygenase 
activity is increased in the brains of Huntington disease victims. Proc Natl Acad Sci U S A. 1988; 
85:4079–4081. [PubMed: 2967497] 
38. Stone TW, Forrest CM, Darlington LG. Kynurenine pathway inhibition as a therapeutic strategy 
for neuroprotection. FEBS J. 2012; 279:1386–1397. [PubMed: 22248239] 
39. Tan L, Yu JT, Tan L. The kynurenine pathway in neurodegenerative diseases: mechanistic and 
therapeutic considerations. J Neurol Sci. 2012; 323:1–8. [PubMed: 22939820] 
40. Obuse C, Iwasaki O, Kiyomitsu T, Goshima G, Toyoda Y, Yanagida M. A conserved Mis12 
centromere complex is linked to heterochromatic HP1 and outer kinetochore protein Zwint-1. Nat 
Cell Biol. 2004; 6:1135–1141. [PubMed: 15502821] 
41. Wang Y, Devereux W, Woster PM, Stewart TM, Hacker A, Casero RA Jr. Cloning and 
characterization of a human polyamine oxidase that is inducible by polyamine analogue exposure. 
Cancer Res. 2001; 61:5370–5373. [PubMed: 11454677] 
42. Aleman A, Cebrian V, Alvarez M, Lopez V, Orenes E, Lopez-Serra L, et al. Identification of 
PMF1 methylation in association with bladder cancer progression. Clin Cancer Res. 2008; 
14:8236–8243. [PubMed: 19088041] 
43. Woo D, Falcone GJ, Devan WJ, Brown WM, Biffi A, Howard TD, et al. Meta-analysis of 
Genome-wide Association Studies Identifies 1q22 as a Susceptibility Locus for Intracerebral 
Hemorrhage. Am J Hum Genet. 2014; 94:511–521. [PubMed: 24656865] 
44. Folsom AR, Yatsuya H, Mosley TH Jr, Psaty BM, Longstreth WT Jr. Risk of intraparenchymal 
hemorrhage with magnetic resonance imaging-defined leukoaraiosis and brain infarcts. Ann 
Neurol. 2012; 71:552–559. [PubMed: 22522444] 
45. Hu B, Thirtamara-Rajamani KK, Sim H, Viapiano MS. Fibulin-3 is uniquely upregulated in 
malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res. 2009; 7:1756–
1770. [PubMed: 19887559] 
46. Hu B, Nandhu MS, Sim H, Agudelo-Garcia PA, Saldivar JC, Dolan CE, et al. Fibulin-3 promotes 
glioma growth and resistance through a novel paracrine regulation of Notch signaling. Cancer Res. 
2012; 72:3873–3885. [PubMed: 22665268] 
47. Just A, Canaple S, Joly H, Piussan C, Rosa A. Neurologic complications in a case of Werner 
syndrome. Rev Neurol (Paris). 1996; 152:634–636. [PubMed: 9033957] 
Verhaaren et al. Page 16













48. De Stefano N, Dotti MT, Battisti C, Sicurelli F, Stromillo ML, Mortilla M, et al. MR evidence of 
structural and metabolic changes in brains of patients with Werner's syndrome. J Neurol. 2003; 
250:1169–1173. [PubMed: 14586596] 
49. Taylor LP. Diagnosis, treatment, and prognosis of glioma: five new things. Neurology. 2010; 
75:S28–S32. [PubMed: 21041768] 
50. Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977–2000. 
Cancer. 2004; 101:2293–2299. [PubMed: 15476282] 
51. Falahati S, Breu M, Waickman AT, Phillips AW, Arauz EJ, Snyder S, et al. Ischemia-induced 
neuroinflammation is associated with disrupted development of oligodendrocyte progenitors in a 
model of periventricular leukomalacia. Dev Neurosci. 2013; 35:182–196. [PubMed: 23445614] 
52. Wakita H, Tomimoto H, Akiguchi I, Kimura J. Glial activation and white matter changes in the rat 
brain induced by chronic cerebral hypoperfusion: an immunohistochemical study. Acta 
Neuropathol. 1994; 87:484–492. [PubMed: 8059601] 
53. Masumura M, Hata R, Nagai Y, Sawada T. Oligodendroglial cell death with DNA fragmentation in 
the white matter under chronic cerebral hypoperfusion: comparison between normotensive and 
spontaneously hypertensive rats. Neurosci Res. 2001; 39:401–412. [PubMed: 11274739] 
Verhaaren et al. Page 17














Regional plots of the genome-wide significant loci in individuals of European descent. Loci 
on chr17q25.1, chr10q24.33, chr2p16.1, chr1q22 and chr2p21 are shown. Each circle 
indicates a SNP with a color scale corresponding to the r2value for that SNP and the top 
SNP from 1000 Genomes. Purple diamonds indicate the SNPs with the strongest association 
in the overall meta-analysis. Estimated recombination from 1000 Genomes are indicated 
blue lines. The bottom panels show the relative position of genes within each locus.
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